The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections-Reference-Cited by-同舟云学术

The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections

Published:2020-05-17 Issue:10 Volume:92 Page:2087-2095
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Musarrat Farhana¹²,Chouljenko Vladimir¹²,Dahal Achyut³,Nabi Rafiq¹²,Chouljenko Tamara⁴,Jois Seetharama D.³,Kousoulas Konstantin G.¹²^ORCID

Affiliation:

1. Division of Biotechnology and Molecular Medicine Louisiana State University Baton Rouge Louisiana

2. Department of Pathobiological Sciences, School of Veterinary Medicine Louisiana State University Baton Rouge Louisiana

3. School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy University of Louisiana Monroe Monroe Louisiana

4. Louisiana State University Agricultural Center Agricultural Biotechnology Laboratory Baton Rouge Louisiana

Funder

Louisiana Board of Regents

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.25985

Reference43 articles.

1. Another Decade, Another Coronavirus

2. A new coronavirus associated with human respiratory disease in China

3. A Novel Coronavirus from Patients with Pneumonia in China, 2019

4. Severe acute respiratory syndrome (SARS): a review of the history, epidemiology, prevention, and concerns for the future

5. Severe acute respiratory syndrome (SARS): a review

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of Spike;Viruses;2024-04-30

2. Drug repurposing: identification of SARS-CoV-2 potential inhibitors by virtual screening and pharmacokinetics strategies;The Journal of Infection in Developing Countries;2024-04-30

3. SARS-CoV-2 mechanisms of cell tropism in various organs considering host factors;Heliyon;2024-02

4. Expression and fusogenic activity of SARS CoV-2 Spike protein displayed in the HSV-1 Virion;2023-11-28

5. Exploring Novel Vitamin K Derivatives with Anti-SARS-CoV-2 Activity;ACS Omega;2023-11-01